US FDA Approved Zhiyi Biotech’s SK10 to Treat Chemotherapy-induced Diarrhea

Zhiyi Biotech has announced that the US Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application of the company to develop SK10 (Inactivated Bacteroids fragilis) for the treatment of Chemotherapy-induced Diarrhea (CID). The approval of the IND application authorizes Zhiyi Biotech to conduct a Phase 1 clinical trial in the United […]

Continue Reading